Ascendia Pharmaceuticals

Ascendia is a specialized pharmaceutical organization committed to developing improved formulations of current drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. Ascendia offers cutting-edge formulation development services for poorly soluble molecules, and cGMP manufacture of materials for clinical trials. By utilizing its nano-particle technologies and expertise, Ascendia can quickly evaluate the feasibility of a wide range of formulation options to enhance a drug’s bioavailability. ACADIA has a history deeply rooted in scientific research and strong leadership in CNS. Since inception, the focus has been on enhancing the lives of patients with CNS disorders. At ACADIA, there is a strong passion for enhancing the lives of patients with central nervous system (CNS) disorders. The goal is to establish a solid foundation to become a leading biopharmaceutical company dedicated to creating and marketing innovative therapies in the CNS field. ACADIA's mission is to be the foremost pharmaceutical company devoted to the advancement of innovative medicines that enhance the lives of patients with central nervous system disorders. Our therapeutic platform aims to significantly improve the effectiveness and safety of medical treatments by harnessing the potential of natural compounds. It is generating a consistent flow of urgently required solutions for both consumer and hospital-based medical needs. Our innovative pharmacotherapeutic platform discovers and maximizes pharmacologic synergies between natural compounds and existing medical treatments, thus remarkably enhancing the effectiveness and safety of current therapies across various applications, including dermatology, hospital-acquired infection, and oncology. Escend Pharmaceuticals, Inc., is developing treatments for rare cancer-related conditions. Our focus in development includes therapies that target cancer stem cells in acute myelogenous leukemia and related blood cancers. Escend has devised a process to expedite drug discovery, utilizing comprehensive biological approaches and risk mitigation strategies to identify common cellular pathways across multiple diseases. We select small molecule drug candidates with established safety profiles that have not yet received US marketing approval, and match these agents with disease indications based on recent scientific evidence.